The Patent Finder

Synthon B.V.

33 patents currently held · Updated Nov 20, 2026
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 3 name spellings.

1
Ending by 2030
Sep 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due May 19, 2027
    The maintenance fee for Modified release tablet composition comprising mirabegron (US 10,478,399) comes due May 19, 2027. Unpaid by Nov 19, 2027, it lapses early.
  • 3 fees due Jul 2 to 28, 2027 · next Jul 2
  • 1 fee due Aug 27, 2027
    The maintenance fee for Pharmaceutical composition comprising Lenvatinib mesylate (US 11,911,509) comes due Aug 27, 2027. Unpaid by Feb 28, 2028, it lapses early.
  • 1 fee due Sep 17, 2027
    The maintenance fee for Pharmaceutical composition comprising sacubitril and valsartan (US 10,588,892) comes due Sep 17, 2027. Unpaid by Mar 17, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 22, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 7,655,798Process of making crystalline Type II aripiprazole
In force
 · USPTO record
In forceUSPTO record
US 8,529,949Pharmaceutical tablets of crystalline type II aripiprazole
In force
 · USPTO record
In forceUSPTO record
US 9,702,866Glatiramer acetate human monocytic cell line-based potency assay
In force
 · USPTO record
In forceUSPTO record
US 9,617,313Process for purifying a polymer mixture
In force
 · USPTO record
In forceUSPTO record
US 10,188,655Liquid pharmaceutical composition comprising pemetrexed
In force
 · USPTO record
In forceUSPTO record
US 10,272,090Liquid Pharmaceutical Composition Comprising Pemetrexed
In force
 · Low confidence
In forceLow confidence
US 10,259,805Process for Making Crystalline Form a of Gefitinib
In force
 · High confidence
In forceHigh confidence
US 10,543,174Modified release tablet composition comprising mirabegron
In force
 · USPTO record
In forceUSPTO record
US 10,894,839Process for making Sugammadex
In force
 · USPTO record
In forceUSPTO record
US 10,478,399Modified release tablet composition comprising mirabegron
In force
 · USPTO record
In forceUSPTO record
10 of 33 patents shown.
Pro members see all 33.
Pro members: see all 33 patents
Also on record, not counted in the 33: 1 patent in force now held by others · 69 lapsed for an unpaid fee · 7 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

9 pending · 3 abandoned · 20 no status recorded

Showing 1 to 10 of 32, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.

ApplicationTitleFiledStatus
18/762,066Pharmaceutical Composition Comprising EnzalutamideJul 2, 2024Pending
19/106,475Aug 25, 2023No status recorded
18/993,276Budesonide Two Layers Capsule FormulationJul 11, 2023Pending
18/842,577Cabozantinib Salt with L-(+)-Tartaric Acid and Solid Forms ThereofFeb 28, 2023Pending
18/840,429Solid Forms of Alectinib and Alectinib SaltsFeb 21, 2023Pending
18/717,130Pharmaceutical Composition Comprising IbrutinibDec 6, 2022Pending
18/690,975Pharmaceutical Composition of Bempedoic AcidSep 12, 2022Pending
18/686,210Sep 1, 2022No status recorded
18/566,329Jun 3, 2022No status recorded
18/565,888Process for Making Melflufen or a Salt ThereofJun 1, 2022Pending
10 of 32 applications shown.
Pro members see all 32 published applications.
Pro members: see all 32 applications
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited